Sickle-cell disease surgery: Difference between revisions

Jump to navigation Jump to search
 
Line 7: Line 7:


==Surgery==
==Surgery==
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either:<ref name="pmid22924029">{{cite journal| author=Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I et al.| title=Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. | journal=ScientificWorldJournal | year= 2012 | volume= 2012 | issue=  | pages= 949535 | pmid=22924029 | doi=10.1100/2012/949535 | pmc=3415156 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22924029  }} </ref><ref name="pmid22924029">{{cite journal| author=Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I et al.| title=Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. | journal=ScientificWorldJournal | year= 2012 | volume= 2012 | issue= | pages= 949535 | pmid=22924029 | doi=10.1100/2012/949535 | pmc=3415156 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22924029  }} </ref>
The mainstay of treatment for sickle cell disease is medical therapy. Surgery is usually reserved for patients with either:<ref name="pmid22924029">{{cite journal| author=Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I et al.| title=Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. | journal=ScientificWorldJournal | year= 2012 | volume= 2012 | issue=  | pages= 949535 | pmid=22924029 | doi=10.1100/2012/949535 | pmc=3415156 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22924029  }} </ref><ref name="pmid16214650">{{cite journal |vauthors=Buck J, Davies SC |title=Surgery in sickle cell disease |journal=Hematol. Oncol. Clin. North Am. |volume=19 |issue=5 |pages=897–902, vii |date=October 2005 |pmid=16214650 |doi=10.1016/j.hoc.2005.07.004 |url=}}</ref>
*First episode of a splenic sequestration crisis
*First episode of a splenic sequestration crisis
*[[Cholecystitis]] or symptoms of [[gallbladder disease]]
*[[Cholecystitis]] or symptoms of [[gallbladder disease]]

Latest revision as of 15:35, 7 August 2018

Sickle-cell disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sickle-cell disease from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Sickle-cell disease surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sickle-cell disease surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Sickle-cell disease surgery

CDC on Sickle-cell disease surgery

Sickle-cell disease surgery in the news

Blogs onSickle-cell disease surgery

Directions to Hospitals Treating Sickle-cell disease

Risk calculators and risk factors for Sickle-cell disease surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]

Overview

Surgical intervention is generally not recommended for the management of sickle-cell disease. However, certain surgeries may be performed for specific complications.

Surgery

The mainstay of treatment for sickle cell disease is medical therapy. Surgery is usually reserved for patients with either:[1][2]

References

  1. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I; et al. (2012). "Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management". ScientificWorldJournal. 2012: 949535. doi:10.1100/2012/949535. PMC 3415156. PMID 22924029.
  2. Buck J, Davies SC (October 2005). "Surgery in sickle cell disease". Hematol. Oncol. Clin. North Am. 19 (5): 897–902, vii. doi:10.1016/j.hoc.2005.07.004. PMID 16214650.